ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Published experience with active surveillance for low-risk prostate cancer in single-institution and multi-institutional nonrandomized cohorts

Published experience with active surveillance for low-risk prostate cancer in single-institution and multi-institutional nonrandomized cohorts
  UCSF[1] Toronto[2] PRIAS[3] Johns Hopkins[4] Canary PASS[5]
Year enrollment commenced 1990 1995 2008 1995 2008
Number of patients 2113 993 5302 1818 1041
Age, median (IQR) 62 68 (41-89) 66 (61-70) 66 (62-69) 63 (58-67)
PSA, median (ng/mL) at time of initiation of surveillance 5.5 (4.2-7.5) 4.8 (3.2-6.6) 5.7 (4.5-7.1) 4.6 (3.5-5.8) 5.0 (3.8-6.5)
Follow-up (months) 73 (43-112) 77 (2-238) 78 (37-101) 68 (31-109) 28 (33.5)
Reclassification during follow-up to grade group (GG) ≥2 41% at 7 years 9.5% at median follow-up 6.4 years 22 to 33%

21% at 5 years

30% at 10 years		 24%
Fraction requiring treatment after initial period of active surveillance 59% at 7 years

24% at 5 years

36% at 10 years

52% at 5 years

73% at 10 years

36% at 5 years

48% at 10 years		 19%
Fraction developing metastasis 1% at 7 years 2.8% Not reported 0.1% at 10 years Not reported
IQR: interquartile range; PSA: prostate specific antigen.
References:
  1. Welty CJ, Cowan JE, Nguyer H, et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 2015; 193:807.
  2. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33:272.
  3. Bokhorst LP, Valdagni R, Rannikko A, et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol 2016; 70:954.
  4. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and lon-ger-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015; 33:3379.
  5. Newcomb LF, Thompson IM, Boyer HD, et al. Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort. J Urol 2016; 195:313.
Graphic 130093 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟